{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:12:32Z","timestamp":1793650352966,"version":"4.5.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The OX40\/OX40L axis entered clinical development in atopic dermatitis with a strong biological rationale and early signs of durable activity. However, as the treatment landscape evolved, questions emerged about whether the magnitude of monotherapy benefit was sufficient relative to established and emerging therapies. The discontinuation of rocatinlimab after confirmed and suspected cutaneous Kaposi\u2019s sarcoma cases, together with two cumulative cases reported in the amlitelimab program in patients with known risk factors, has changed the discussion from early promise to mechanism, risk, and therapeutic strategy. Although a causal link between OX40\/OX40L modulation and Kaposi\u2019s sarcoma remains unproven, available human genetic and experimental observations make the association biologically plausible but mechanistically unresolved. The central challenge is now to determine how the axis can be targeted, in which patients, and in what therapeutic context, to maximize clinical benefit while managing risk. Rather than signaling the end of the axis in atopic dermatitis, Kaposi\u2019s sarcoma may instead mark the limits of a first-generation development strategy and the beginning of a more selective approach built around molecule design, therapeutic context, and prospective risk mitigation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1870289","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:29Z","timestamp":1780374509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Is Kaposi\u2019s sarcoma the end of the OX40\/OX40L axis in atopic dermatitis?"],"prefix":"10.3389","volume":"17","author":[{"given":"Shahram","family":"Salek-Ardakani","sequence":"first","affiliation":[{"name":"YZ Consulting","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00149-x","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00838-9","article-title":"OX40 in the pathogenesis of atopic dermatitis-a new therapeutic target","volume":"25","author":"Croft","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.70252","article-title":"The OX40\/OX40L axis promotes Th2 activity and impairs regulatory T cell function in atopic dermatitis","author":"Yamamura","year":"2026","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.016","article-title":"Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets","volume":"128","author":"Fujita","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3452","article-title":"The OX40 axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04587.x","article-title":"OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity","volume":"27","author":"Ilves","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00403-024-03426-x","article-title":"Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab","volume":"316","author":"Guttman-Yassky","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human non-depleting, non-cytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"B16","first-page":"1","article-title":"OX40 ligand inhibitors for moderate-to-severe atopic dermatitis: a review of phase II clinical trial data","volume":"30","author":"Sood","year":"2025","journal-title":"Skin Ther Lett"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01609-6","article-title":"A post hoc analysis of atopic dermatitis of the head and neck and other body regions from the amlitelimab STREAM-AD phase 2b study","volume":"16","author":"Reich","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B18","unstructured":"Press release: Sanofi's amlitelimab confirms its potential in atopic dermatitis\n          \n          \n          \n          2026"},{"key":"B19","unstructured":"Kyowa Kirin to regain control of rocatinlimab development and commercialization program from Amgen\n          \n          \n          \n          2026"},{"key":"B20","unstructured":"Kyowa Kirin announces discontinuation of rocatinlimab clinical trials\n          \n          \n          \n          2026"},{"key":"B21","unstructured":"AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session\n          \n          \n          \n          2026"},{"key":"B22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/1750743X.2025.2464528","article-title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis","volume":"17","author":"Guttman-Yassky","year":"2025","journal-title":"Immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(25)01865-3","article-title":"Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials","volume":"407","author":"Guttman-Yassky","year":"2026","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1093\/bjd\/ljad498.028","article-title":"Efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis: 24-week results from the phase 2b STREAM-AD trial","volume":"143","author":"Weidinger","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130592","article-title":"Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood","volume":"210","author":"Byun","year":"2013","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000312","article-title":"OX40 and 4-1BB downregulate Kaposi's sarcoma-associated herpesvirus replication in lymphatic endothelial cells, but 4-1BB and not OX40 inhibits viral replication in B-cells","volume":"96","author":"Cho","year":"2015","journal-title":"J Gen Virol"},{"key":"B28","unstructured":"Our product pipeline\n          \n          \n          \n          2026"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:31Z","timestamp":1780374511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1870289"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1870289","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1870289"}}